MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 201–300 of 1,006
Wu, D., Kang, L., Tian, J., Wu, Y., Liu, J., Li, Z., Wu, X., Huang, Y., Gao, B., Wang, H., et al. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s275650 · Cited by 196
“Studies have shown that miR-21 can target SPRY in HUVECs to induce the activation of the PI3K/AKT and ERK1/2 pathways, and the activation of the PI3K/AKT and ERK1/2 signaling pathways has been demonstrated to stimulate multiple critical steps in angiogenesis and fibroblast function.(13,20,21) To determine whether miR-…”
BackgroundGrundmann, S., Hans, F. P., Kinniry, S., Heinke, J., Helbing, T., Bluhm, F., Sluijter, J. P. G., Hoefer, I., Pasterkamp, G., Bode, C., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.000323 · Cited by 198
Cardiac fibrosis: potential therapeutic targets
Park, S., Nguyen, N. B., Pezhouman, A., & Ardehali, R. (2019) · Translational Research · doi:10.1016/j.trsl.2019.03.001 · Cited by 194
MicroRNA therapeutics in cardiovascular medicine
Thum, T. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100191 · Cited by 193
“Initially, primary miRNAs (pri-miRNA) are generated in the cellular nucleus by the transcription machinery and are then processed by the RNase-III-type enzyme Drosha to form so-called precursor miRNAs (pre-miRNAs; Lee et al, 2003; Thum et al, 2008a).”
InfluentialSelf-citationmiR-21 Regulates Skin Wound Healing by Targeting Multiple Aspects of the Healing Process
Wang, T., Feng, Y., Sun, H., Zhang, L., Hao, L., Shi, C., Wang, J., Li, R., Ran, X., Su, Y., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.022 · Cited by 192
A guide to miRNAs in inflammation and innate immune responses
Nejad, C., Stunden, H. J., & Gantier, M. P. (2018) · The FEBS Journal · doi:10.1111/febs.14482 · Cited by 191
Cardin, S., Guasch, E., Luo, X., Naud, P., Le Quang, K., Shi, Y., Tardif, J.-C., Comtois, P., & Nattel, S. (2012) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.112.973214 · Cited by 189
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Self-citationWang, Y., Li, L., Moore, B. T., Peng, X.-H., Fang, X., Lappe, J. M., Recker, R. R., & Xiao, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034641 · Cited by 188
“MiRNAs have been identified as important biomarkers and regulators in various human diseases such as cancer [1,2], diabetes [3,4] and myocardial disease [5].”
BackgroundThe Transcardiac Gradient of Cardio-Micrornas in the Failing Heart
Marques, F. Z., Vizi, D., Khammy, O., Mariani, J. A., & Kaye, D. M. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.517 · Cited by 187
Mensà, E., Guescini, M., Giuliani, A., Bacalini, M. G., Ramini, D., Corleone, G., Ferracin, M., Fulgenzi, G., Graciotti, L., Prattichizzo, F., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2020.1725285 · Cited by 187
“MiR-21-5p over-expression has also been related to the development of cardiac fibrosis [70], T-cell subset alteration [71] and imbalances in platelet function [72], all functions that are affected by ageing.”
BackgroundMicroRNAs in age‐related diseases
Dimmeler, S., & Nicotera, P. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201986 · Cited by 188
“…and miRNA clusters, only the upregulation of miR-21 has been validated in this study (Zhang et al, 2012b). miR-21 is known for its profibrotic activity (Thum et al, 2008), which may well fit in the context of cardiac aging, but the precise function during cardiac aging remains to be determined.”
Fleissner, F., Jazbutyte, V., Fiedler, J., Gupta, S. K., Yin, X., Xu, Q., Galuppo, P., Kneitz, S., Mayr, M., Ertl, G., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.216770 · Cited by 186
Self-citationMicroRNAs with a nucleolar location
Ritland Politz, J. C., Hogan, E. M., & Pederson, T. (2009) · RNA · doi:10.1261/rna.1470409 · Cited by 184
“We were also interested in miR-199a-3p and miR-21 because they had been shown to increase during cardiac hypertrophy (van Rooij et al. 2006; Thum et al. 2008) and Duchenne muscular dystrophy (Eisenberg et al.”
BackgroundMicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart
Jazbutyte, V., Fiedler, J., Kneitz, S., Galuppo, P., Just, A., Holzmann, A., Bauersachs, J., & Thum, T. (2013) · AGE · doi:10.1007/s11357-012-9407-9 · Cited by 185
Self-citationLiu, Y., Li, Q., Hosen, M. R., Zietzer, A., Flender, A., Levermann, P., Schmitz, T., Frühwald, D., Goody, P., Nickenig, G., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314010 · Cited by 186
MicroRNAs in Diabetes: Tiny Players in Big Disease
Pandey, A. K., Agarwal, P., Kaur, K., & Datta, M. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000218169 · Cited by 181
Novel molecular targets for atrial fibrillation therapy
Dobrev, D., Carlsson, L., & Nattel, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3682 · Cited by 181
“Fibroblast survival is regulated by the protein sprouty homolog 1, which is under the control of miR-21 (Ref”
BackgroundFrom Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer
Rhim, J., Baek, W., Seo, Y., & Kim, J. H. (2022) · Cells · doi:10.3390/cells11182791 · Cited by 175
Chung, A. C.-K., & Lan, H. Y. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00050 · Cited by 180
“MICRORNAs IN TGF-β-INDUCED RENAL FIBROSIS”
BackgroundInfluentialYang, L., Wang, B., Zhou, Q., Wang, Y., Liu, X., Liu, Z., & Zhan, Z. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0805-5 · Cited by 178
Long, G., Wang, F., Duan, Q., Chen, F., Yang, S., Gong, W., Wang, Y., Chen, C., & Wang, D. W. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4439 · Cited by 178
“In recent years, tremendous efforts have been made to use a miRNA microarray screening approach to address the miRNA expression profiling in infarted hearts from animal models [28-30].”
BackgroundShin, Y. J., Shafranek, R. T., Tsui, J. H., Walcott, J., Nelson, A., & Kim, D.-H. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.11.006 · Cited by 174
Atrial Fibrillation: Mechanisms, Therapeutics, and Future Directions
Pellman, J., & Sheikh, F. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140047 · Cited by 218
O'Connell, P. J., Zhang, W., Menon, M. C., Yi, Z., Schröppel, B., Gallon, L., Luan, Y., Rosales, I. A., Ge, Y., Losic, B., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30826-1 · Cited by 177
Li, H., Zhang, X., Wang, F., Zhou, L., Yin, Z., Fan, J., Nie, X., Wang, P., Fu, X.-D., Chen, C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.023926 · Cited by 176
Zhang, J., Cheng, Y., Cui, W., Li, M., Li, B., & Guo, L. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.09.019 · Cited by 179
Patel, V., & Noureddine, L. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e328354e559 · Cited by 176
“miR-21 is upregulated in cardiac fibroblasts in failing mouse and human hearts, and antimiRmediated inhibition of miR-21 attenuates fibrosis and improves cardiac function in mouse models of heart failure [11].”
BackgroundNew Targets to Treat the Structural Remodeling of the Myocardium
González, A., Ravassa, S., Beaumont, J., López, B., & Díez, J. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.058 · Cited by 176
MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation
Li, Q., Zhang, D., Wang, Y., Sun, P., Hou, X., Larner, J., Xiong, W., & Mi, J. (2013) · Scientific Reports · doi:10.1038/srep02038 · Cited by 176
A Resource for the Conditional Ablation of microRNAs in the Mouse
Park, C. Y., Jeker, L. T., Carver-Moore, K., Oh, A., Liu, H. J., Cameron, R., Richards, H., Li, Z., Adler, D., Yoshinaga, Y., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.008 · Cited by 176
“, 2005); however, the discrepancy between genetic ablation and the in vivo use of miRNA inhibitors has raised questions about this approach in mice (Patrick et al., 2010; Thum et al., 2008).”
BackgroundmicroRNA: Emerging therapeutic targets in acute ischemic diseases
Fasanaro, P., Greco, S., Ivan, M., Capogrossi, M. C., & Martelli, F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.003 · Cited by 174
“In keeping with these findings, miR-21 levels are also selectively increased in fibroblasts of the failing heart, upregulating ERK-MAP kinase activity through inhibition of Sprouty homologue 1 (Thum et al., 2008).”
Profibrotic Role of miR-154 in Pulmonary Fibrosis
Milosevic, J., Pandit, K., Magister, M., Rabinovich, E., Ellwanger, D. C., Yu, G., Vuga, L. J., Weksler, B., Benos, P. V., Gibson, K. F., et al. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0377oc · Cited by 175
Involvement of miRNAs in ovarian follicular and luteal development
Donadeu, F. X., Schauer, S. N., & Sontakke, S. D. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0252 · Cited by 173
“…in miR-21 contributes to follicular cell survival associated with the follicle–luteal transition, a conclusion that is well in line with the described anti-apoptotic role of miR-21 in other normal tissues including cardiac and hematopoietic (Thum et al. 2008, Roy et al. 2009, Sheedy et al. 2010).”
Loyer, X., Paradis, V., Hénique, C., Vion, A.-C., Colnot, N., Guerin, C. L., Devue, C., On, S., Scetbun, J., Romain, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308883 · Cited by 171
Yuan, J., Liu, H., Gao, W., Zhang, L., Ye, Y., Yuan, L., Ding, Z., Wu, J., Kang, L., Zhang, X., et al. (2018) · Theranostics · doi:10.7150/thno.22878 · Cited by 173
“Growing evidence has indicated that many miRNAs exist that are aberrantly expressed in response to hemodynamic pressure overload in humans and mice and that they control and/or modulate key components of the hypertrophic and fibrotic process during cardiac remodeling [8-12].”
BackgroundYamaguchi, T., Izumi, Y., Nakamura, Y., Yamazaki, T., Shiota, M., Sano, S., Tanaka, M., Osada-Oka, M., Shimada, K., Miura, K., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.144 · Cited by 174
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Kota, J., Hancock, J., Kwon, J., & Korc, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.035 · Cited by 173
Cardiac Nonmyocytes in the Hub of Cardiac Hypertrophy
Kamo, T., Akazawa, H., & Komuro, I. (2015) · Circulation Research · doi:10.1161/circresaha.117.305349 · Cited by 171
“For instance, miR-21 in cardiac fibroblasts promoted cardiomyocyte hypertrophy by regulating the expression of growth factors, such as FGF-2, as well as ECM protein synthesis.(82) In contrast, miR-29b in cardiac fibroblasts reduced ECM protein deposition, and conditioned medium of cardiac fibroblasts transfected with…”
BackgroundGhosh, A. K., Nagpal, V., Covington, J. W., Michaels, M. A., & Vaughan, D. E. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2011.12.024 · Cited by 170
Functions of MicroRNAs in Cardiovascular Biology and Disease
Hata, A. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183737 · Cited by 171
“Downregulation of miR-21 with cholesterol-modified ASO against miR-21 in mice attenuates cardiac remodeling following thoracic aortic banding (76).”
Faedo, A., Borello, U., & Rubenstein, J. L. R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0307-10.2010 · Cited by 169
“The Spry1 lacz strain was used (Thum et al., 2008).”
BackgroundMethodInfluentialNoncoding RNAs and myocardial fibrosis
Thum, T. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.125 · Cited by 173
Self-citationCissell, K. A., & Deo, S. K. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-2744-6 · Cited by 169
Role of microRNAs in the reperfused myocardium towards post-infarct remodelling
Zhu, H., & Fan, G.-C. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr291 · Cited by 168
“33,56 Thum et al. 56 showed that knockdown of miR-21 with antagomiRs mitigated interstitial fibrosis and cardiac remodelling after aortic banding.”
BackgroundInfluentialFunction and fate of myofibroblasts after myocardial infarction
Turner, N. A., & Porter, K. E. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-5 · Cited by 171
“In that study, miR-21 targeting of Sprouty homologue, a negative regulator of the mitogen-activated protein kinase signalling pathway, led to increased fibroblast growth factor secretion, fibroblast survival and increased fibrosis [54].”
BackgroundVettori, S., Gay, S., & Distler, O. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010130 · Cited by 172
Mayourian, J., Ceholski, D. K., Gorski, P. A., Mathiyalagan, P., Murphy, J. F., Salazar, S. I., Stillitano, F., Hare, J. M., Sahoo, S., Hajjar, R. J., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.312420 · Cited by 168
MicroRNAs and cardiovascular diseases
Ono, K., Kuwabara, Y., & Han, J. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08090.x · Cited by 169
The Living Scar – Cardiac Fibroblasts and the Injured Heart
Rog-Zielinska, E. A., Norris, R. A., Kohl, P., & Markwald, R. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.12.006 · Cited by 171
A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis
Liang, H., Zhang, C., Ban, T., Liu, Y., Mei, L., Piao, X., Zhao, D., Lu, Y., Chu, W., & Yang, B. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.019 · Cited by 169
Extracellular Matrix Secretion by Cardiac Fibroblasts: Role of MicroRNA-29b and MicroRNA-30c
Abonnenc, M., Nabeebaccus, A. A., Mayr, U., Barallobre-Barreiro, J., Dong, X., Cuello, F., Sur, S., Drozdov, I., Langley, S. R., Lu, R., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.302400 · Cited by 168
“miR-21 has also been implicated in cardiac fibrosis, but its role is debated.(7,8)”
BackgroundClinical applications of microRNAs
Hydbring, P., & Badalian‐Very, G. (2013) · F1000Research · doi:10.12688/f1000research.2-136.v3 · Cited by 130
Biogenesis and Regulation of Cardiovascular MicroRNAs
Bauersachs, J., & Thum, T. (2011) · Circulation Research · doi:10.1161/circresaha.110.228676 · Cited by 169
Self-citationRole of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease
He, J., Xu, Y., Koya, D., & Kanasaki, K. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0781-0 · Cited by 167
Circulating MicroRNAs and Aerobic Fitness – The HUNT-Study
Bye, A., Røsjø, H., Aspenes, S. T., Condorelli, G., Omland, T., & Wisløff, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057496 · Cited by 165
“Artherosclerotic plaque [49] Heart failure [41] Stress [42]”
BackgroundMir-30d Regulates Cardiac Remodeling by Intracellular and Paracrine Signaling
Li, J., Salvador, A. M., Li, G., Valkov, N., Ziegler, O., Yeri, A., Yang Xiao, C., Meechoovet, B., Alsop, E., Rodosthenous, R. S., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317244 · Cited by 165
Latella, G., Rogler, G., Bamias, G., Breynaert, C., Florholmen, J., Pellino, G., Reif, S., Speca, S., & Lawrance, I. C. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.03.008 · Cited by 164
Masci, P. G., Schuurman, R., Andrea, B., Ripoli, A., Coceani, M., Chiappino, S., Todiere, G., Srebot, V., Passino, C., Aquaro, G. D., et al. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.113.000438 · Cited by 164
“Moderate/severe MR 16 (28) 7 (32) 9 (25) 0.”
miR‐145 regulates myofibroblast differentiation and lung fibrosis
Yang, S., Cui, H., Xie, N., Icyuz, M., Banerjee, S., Antony, V. B., Abraham, E., Thannickal, V. J., & Liu, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-219493 · Cited by 165
MicroRNAs in fibrosis: opportunities and challenges
O’Reilly, S. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0929-x · Cited by 165
“Furthermore, miRNA-21 is overexpressed in heart disease, and in a pressure overload model it was found that miRNA-21 overexpression modulates cardiac myocyte hypertrophy and interstitial fibrosis through reduction of sprouty homologue-1, a potent inhibitor of the extracellular regulated kinase/mitogen-activated protei…”
BackgroundWang, M., Li, W., Chang, G.-Q., Ye, C.-S., Ou, J.-S., Li, X.-X., Liu, Y., Cheang, T.-Y., Huang, X.-L., & Wang, S.-M. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.229559 · Cited by 166
MicroRNA Expression and Virulence in Pandemic Influenza Virus-Infected Mice
Li, Y., Chan, E. Y., Li, J., Ni, C., Peng, X., Rosenzweig, E., Tumpey, T. M., & Katze, M. G. (2010) · Journal of Virology · doi:10.1128/jvi.02203-09 · Cited by 164
“For example, miR-34a acts as a tumor suppressor by inhibiting the expression of sirt1 (40), whereas miR-21 contributes to myocardial disease by inhibiting the expression of spry1 (36).”
BackgroundTian, C., Gao, L., Zimmerman, M. C., & Zucker, I. H. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00602.2017 · Cited by 163
Shi, C., Liang, Y., Yang, J., Xia, Y., Chen, H., Han, H., Yang, Y., Wu, W., Gao, R., & Qin, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066814 · Cited by 161
Wei, Z., Chen, Z., Zhao, Y., Fan, F., Xiong, W., Song, S., Yin, Y., Hu, J., Yang, K., Yang, L., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121000 · Cited by 163
MicroRNAs, transforming growth factor beta‐1, and tissue fibrosis
Bowen, T., Jenkins, R. H., & Fraser, D. J. (2013) · The Journal of Pathology · doi:10.1002/path.4119 · Cited by 163
Zhu, H., Luo, H., Li, Y., Zhou, Y., Jiang, Y., Chai, J., Xiao, X., You, Y., & Zuo, X. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9896-z · Cited by 162
“Previous studies showed that miR-21 regulates lung, heart, renal fibrosis by enhancing the fibrogenic activity or promoting the proliferation of interstitial fibroblasts [20–22].”
BackgroundmicroRNAs in heart disease: putative novel therapeutic targets?
Condorelli, G., Latronico, M. V. G., & Dorn, G. W. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp573 · Cited by 165
New paradigms in inflammatory signaling in vascular endothelial cells
Xiao, L., Liu, Y., & Wang, N. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00182.2013 · Cited by 160
“The validated targets of miR-21 include ras homolog family member B (Rho B) (48, 89), phosphatase and tensin homolog (PTEN) (67), peroxisome proliferator-activated receptor- (PPAR ) in ECs (120) and Sprouty 1 (103) and 2 (32), programmed cell death protein 4 (PDCD4) (6), B-cell lymphoma 2 (Bcl-2), transforming growth…”
BackgroundMicroRNAs and Their Role in Progressive Kidney Diseases
Kato, M., Arce, L., & Natarajan, R. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00520109 · Cited by 158
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study
Haghikia, A., Haghikia, A., Hellwig, K., Baraniskin, A., Holzmann, A., Décard, B. F., Thum, T., & Gold, R. (2012) · Neurology · doi:10.1212/wnl.0b013e3182759621 · Cited by 161
Self-citationFrolova, E. G., Sopko, N., Blech, L., Popović, Z. B., Li, J., Vasanji, A., Drumm, C., Krukovets, I., Jain, M. K., Penn, M. S., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190728 · Cited by 163
“for microRNA-21 (41): miR-21 was expressed in cardiac”
BackgroundMicroRNAs: critical mediators of differentiation, development and disease
Friedman, J., & Jones, P. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12794 · Cited by 159
Plasminogen Activator Inhibitor Type‐1 as a Regulator of Fibrosis
Rabieian, R., Boshtam, M., Zareei, M., Kouhpayeh, S., Masoudifar, A., & Mirzaei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26146 · Cited by 161
Lu, Q.-B., Ding, Y., Liu, Y., Wang, Z.-C., Wu, Y., Niu, K.-M., Li, K., Zhang, J., & Sun, H. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.014 · Cited by 159
The emerging role of miRNAs in inflammatory bowel disease: a review
Chapman, C. G., & Pekow, J. R. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14547360 · Cited by 173
RNA Therapeutics in Cardiovascular Disease
Lucas, T., Bonauer, A., & Dimmeler, S. (2018) · Circulation Research · doi:10.1161/circresaha.117.311311 · Cited by 156
Application of micro RNA s in diagnosis and treatment of cardiovascular disease
Wronska, A., Kurkowska‐Jastrzebska, I., & Santulli, G. (2015) · Acta Physiologica · doi:10.1111/apha.12416 · Cited by 158
“…in a CVD model, where the injection of a chemically modified anti-miR-21 was shown to improve structural and functional cardiac characteristics in two different murine models, offering the first in vivo confirmation of the great therapeutic potential of miRNA modulation (Thum et al. 2008).”
BackgroundmicroRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis
Noetel, A., Kwiecinski, M., Elfimova, N., Huang, J., & Odenthal, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00049 · Cited by 157
“…three bases. miR-29a and miR-29b1 as well as miR-29c and miR-29b2, are encoded and transcribed in tandem by two genes located on chromosome 7 or chromosome 1, respectively (Mott et al., 2007; Wang et al., 2008). van Rooij et al. (2008) first reported the miR-29 function after myocardial infarction.”
Role of microRNAs in Lung Development and Pulmonary Diseases
Sessa, R., & Hata, A. (2013) · Pulmonary Circulation · doi:10.4103/2045-8932.114758 · Cited by 179
The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction
Mouillet, J., Chu, T., Hubel, C. A., Nelson, D. M., Parks, W. T., & Sadovsky, Y. (2010) · Placenta · doi:10.1016/j.placenta.2010.07.001 · Cited by 170
“Consistent with their vast regulatory potential, miRNAs are involved in many cellular processes, including cell differentiation, proliferation, apoptosis, and metabolic homeostasis, as well as pathological processes such as viral infections [8], cardiovascular diseases [9], and cancer [10–14].”
MicroRNAs as Important Regulators of Exercise Adaptation
Silva, G. J. J., Bye, A., el Azzouzi, H., & Wisløff, U. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.06.003 · Cited by 155
The developing story of Sprouty and cancer
Masoumi-Moghaddam, S., Amini, A., & Morris, D. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9497-1 · Cited by 150
“In line with earlier studies suggesting Sprouty genes as targets of miR-21 [161–163], they proposed that Spry2 is negatively regulated by miR-21 and that such interaction may play a role in colon cancer carcinogenesis.”
ResultBelevych, A. E., Sansom, S. E., Terentyeva, R., Ho, H.-T., Nishijima, Y., Martin, M. M., Jindal, H. K., Rochira, J. A., Kunitomo, Y., Abdellatif, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028324 · Cited by 155
“HF, cardiac fibrosis and ischemia [20,23,24,25,26,37,38].”
miR-133: A Suppressor of Cardiac Remodeling?
Li, N., Zhou, H., & Tang, Q. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00903 · Cited by 172
“Additionally, miR-21 has been also shown to promote the transduction of extracellular signal-regulated kinase/extracellular signal-regulated kinases—mitogen-activated protein kinase (ERK-MAPK) signals, thus aggravating cardiac fibrosis and deteriorating cardiac function (Thum et al., 2008).”
BackgroundDifferential Expression of MicroRNAs in Different Disease States
Abdellatif, M. (2012) · Circulation Research · doi:10.1161/circresaha.111.247437 · Cited by 168
Novel Risk Markers and Risk Assessments for Cardiovascular Disease
Thomas, M. R., & Lip, G. Y. H. (2017) · Circulation Research · doi:10.1161/circresaha.116.309955 · Cited by 173
“miR-21 Fibrosis Role in myocardial remodeling and fibrosis.(98)”
BackgroundCirculating cardiovascular microRNAs in critically ill COVID ‐19 patients
Garg, A., Seeliger, B., Derda, A. A., Xiao, K., Gietz, A., Scherf, K., Sonnenschein, K., Pink, I., Hoeper, M. M., Welte, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2096 · Cited by 163
Self-citationMicroRNAs as therapeutic targets in cardiovascular disease
Laggerbauer, B., & Engelhardt, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159179 · Cited by 168
“miR-21-5p Human, mouse, pig ↑ HF, ↑ TAC (mouse), I/R (pig) miR-21 inhibition or KO prevents and retains cardiac function (44, 79, 81)”
BackgroundInfluentialSelf-citationOsipova, J., Fischer, D., Dangwal, S., Volkmann, I. R., Widera, C., Schwarz, K., Lorenzen, J. M., Schreiver, C., Jacoby, U., Heimhalt, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3868 · Cited by 156
“MiR-21 is known to induce fibrosis in many organs including heart and kidney (5) (19) and promotes TGF-beta mediated effects on endothelial dysfunction and endothelial-to-mesenchymal transition (6).”
BackgroundSelf-citationYang, Y., Ago, T., Zhai, P., Abdellatif, M., & Sadoshima, J. (2010) · Circulation Research · doi:10.1161/circresaha.110.228437 · Cited by 156
Bandyopadhyay, S., Friedman, R. C., Marquez, R. T., Keck, K., Kong, B., Icardi, M. S., Brown, K. E., Burge, C. B., Schmidt, W. N., Wang, Y., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir186 · Cited by 162
“In agreement with our observation, recent studies have established a role for miR-29 and other miRNAs in fibrogenesis of various organs, including heart [19, 29, 30], kidney [20, 31, 32], bone [21], and lung [33]; however, the role of miRNAs in liver fibrosis is only beginning to be explored (reviewed in [34]).”
ResultGene Therapy for the Heart Lessons Learned and Future Perspectives
Cannata, A. N., Ali, H., Sinagra, G., & Giacca, M. (2020) · Circulation Research · doi:10.1161/circresaha.120.315855 · Cited by 163
Boele, J., Persson, H., Shin, J. W., Ishizu, Y., Newie, I. S., Søkilde, R., Hawkins, S. M., Coarfa, C., Ikeda, K., Takayama, K.-I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317751111 · Cited by 153
“U G U C G G G U A G C U U A U C A G A C U G A U G U U G A C U G U U G A A U CU CAUGGCAACACCAGUCGAUGGGCUGUCUGACA 5’ 3’ pre-miR-21 stem-loop miR-21 miR-21+C miR-21+CA apoptosis PAPD5 AGO RISC/miR-21 angiogenesisMAP kinase signaling SERPINB5 PTEN PDCD4 AAAAAAA TP53 mRNA miR-122 miR-122+A PAPD4 CPEB enhanced anaerobic met…”
BackgroundBrock, M., Samillan, V. J., Trenkmann, M., Schwarzwald, C. C., Ulrich, S., Gay, R. E., Gassmann, M., Østergaard, L., Gay, S., Speich, R., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs060 · Cited by 152
Ramanujam, D. P., Schön, A. P., Beck, C. M., Vaccarello, P., Felician, G., Dueck, A., Esfandyari, D., Meister, G., Meitinger, T., Schulz, C., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050682 · Cited by 169
Self-citationLeft Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment
Leancă, S. A., Crișu, D., Petriş, A. O., Afrăsânie, I., Genes, A., Costache, A. D., Tesloianu, D. N., & Costache, I. I. (2022) · Life · doi:10.3390/life12081111 · Cited by 205
Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas
Kwak, H.-J., Kim, Y.-J., Chun, K.-R., Woo, Y. M., Park, S.-J., Jeong, J.-A., Jo, S. H., Kim, T. H., Min, H. S., Chae, J. S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.620 · Cited by 151
“Similarly, miR-21 augmented MAPK signaling through inhibition of Spry1 in cardiac fibroblasts (Thum et al., 2008).”
BackgroundMicroRNAs in the Pathobiology and Therapy of Atherosclerosis
Laffont, B., & Rayner, K. J. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.01.001 · Cited by 153
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.